- Home
- FORA vs HOWL Comparison
FORA vs HOWL Comparison
Compare FORA & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- HOWL
- Stock Information
- Founded
- FORA 2014
- HOWL 2017
- Country
- FORA United States
- HOWL United States
- Employees
- FORA N/A
- HOWL N/A
- Industry
- FORA Computer Software: Prepackaged Software
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- HOWL Health Care
- Exchange
- FORA Nasdaq
- HOWL Nasdaq
- Market Cap
- FORA 69.4M
- HOWL 64.5M
- IPO Year
- FORA N/A
- HOWL 2021
- Fundamental
- Price
- FORA $2.11
- HOWL $0.86
- Analyst Decision
- FORA
- HOWL Strong Buy
- Analyst Count
- FORA 0
- HOWL 5
- Target Price
- FORA N/A
- HOWL $7.00
- AVG Volume (30 Days)
- FORA 39.0K
- HOWL 731.0K
- Earning Date
- FORA 11-14-2025
- HOWL 11-04-2025
- Dividend Yield
- FORA N/A
- HOWL N/A
- EPS Growth
- FORA N/A
- HOWL N/A
- EPS
- FORA N/A
- HOWL N/A
- Revenue
- FORA $28,106,911.00
- HOWL N/A
- Revenue This Year
- FORA $47.82
- HOWL N/A
- Revenue Next Year
- FORA $10.11
- HOWL N/A
- P/E Ratio
- FORA N/A
- HOWL N/A
- Revenue Growth
- FORA 37.47
- HOWL N/A
- 52 Week Low
- FORA $1.64
- HOWL $0.60
- 52 Week High
- FORA $4.03
- HOWL $2.38
- Technical
- Relative Strength Index (RSI)
- FORA 44.32
- HOWL 22.79
- Support Level
- FORA $2.05
- HOWL $0.89
- Resistance Level
- FORA $2.30
- HOWL $1.00
- Average True Range (ATR)
- FORA 0.10
- HOWL 0.10
- MACD
- FORA -0.01
- HOWL -0.03
- Stochastic Oscillator
- FORA 28.78
- HOWL 1.98
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.